Skip to content

The Effects of Tegileridine and Sufentanil on Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Cholecystectomy under Multimodal Antiemetic Strategy: A Prospective, Randomized Controlled Study

The Effects of Tegileridine and Sufentanil on Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Cholecystectomy under Multimodal Antiemetic Strategy: A Prospective, Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111528
Enrollment
Unknown
Registered
2025-11-01
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

Intervention group:Before anesthesia induction, 1mg of tapentadol was intravenously infused via a pump (Tapentadol is a colorless and clear liquid
1mg of tapentadol should be diluted to 20ml, and the administration should be completed within 10 minutes).
Control Group:Before anesthesia induction, the same dose of normal saline was intravenously infused via a pump, and the administration was completed within 10 minutes.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.American Society of Anesthesiologists (ASA) Physical Condition Classification I-II; 2. Age: 18 to 65 years old; 3. Female patients scheduled for laparoscopic cholecystectomy.

Exclusion criteria

Exclusion criteria: 1. Allergic to or having contraindications to the investigational drugs; 2. Preoperative lack of communication ability (coma, deep dementia or language disorder); 3. Severe hypertension (systolic blood pressure >=180mmHg, diastolic blood pressure >=110mmHg) 4. Have a history of serious liver, kidney, lung or heart diseases; 5. There is a history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis before the operation; 6. Have a history of chronic opioid use; 7. Take CYP2D6 and CYP3A inhibitors two weeks before the operation; 8. Pregnant and lactating women; 9. Combined with gastrointestinal peristaltic dysfunction.

Design outcomes

Primary

MeasureTime frame
The overall incidence of postoperative nausea and vomiting (PONV) within 24 hours after surgery;

Secondary

MeasureTime frame
The incidence of nausea and vomiting within 0-6 hours and 6-24 hours after the operation;The number of times nausea or vomiting occurred within 24 hours after the operation;The severity of nausea and vomiting within 24 hours after the operation;The remedial dosage of antiemetic and analgesic drugs within 24 hours after the operation;The time of first getting out of bed;Time of first meal;The pain scores at 6 hours, 12 hours and 24 hours after the operation;The occurrence of complications such as respiratory depression and urinary retention 24 hours after the operation;The time of the first anal exhaust/defecation;The occurrence of intraoperative hypotension and bradycardia;QoR-15 score 24 hours after the operation;Postoperative discharge time;

Countries

China

Contacts

Public ContactXiaoqiang Li

West China Hospital, Sichuan University

877801248@qq.com+86 60660476

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 8, 2026